tiprankstipranks
Trending News
More News >
ProQR Therapeutics BV (PRQR)
:PRQR
Advertisement

ProQR (PRQR) AI Stock Analysis

Compare
1,084 Followers

Top Page

PRQR

ProQR

(NASDAQ:PRQR)

Rating:51Neutral
Price Target:
$2.00
▼(-4.76%Downside)
ProQR's overall stock score is primarily impacted by its financial performance, with strong revenue growth but ongoing profitability challenges. Technical analysis indicates a moderately positive trend, though valuation metrics show significant concerns with negative earnings. The lack of earnings call data and corporate events leaves these areas unassessed.
Positive Factors
Partnerships and Collaborations
Partnership with Eli Lilly underscores platform value and opens the door for milestone payments down the road.
Technological Advancements
ProQR has identified the clinical GalNAc conjugate which will be moving to this clinic this year, with a 5.5-fold increase in potency over early generation NTCP editing oligo.
Negative Factors
Clinical Trials and Data
The first clinical data of AX-0810 in healthy volunteers will provide key information regarding target engagement and biomarkers.

ProQR (PRQR) vs. SPDR S&P 500 ETF (SPY)

ProQR Business Overview & Revenue Model

Company DescriptionProQR Therapeutics N.V. (PRQR) is a biotechnology company focused on developing transformative RNA therapies for the treatment of severe genetic rare diseases. Founded in 2012 and headquartered in Leiden, Netherlands, the company is committed to creating innovative treatments for conditions that currently lack effective therapeutic options. ProQR's pipeline primarily targets genetic disorders affecting vision, such as Leber congenital amaurosis and Usher syndrome, by using its proprietary RNA technology platform.
How the Company Makes MoneyProQR Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These collaborations often involve licensing agreements, research funding, milestone payments, and royalties on product sales. Additionally, the company may receive grant funding from various institutions to support its research and development efforts. ProQR's financial performance largely depends on the successful advancement of its clinical pipeline and securing partnerships to commercialize its RNA therapy candidates.

ProQR Financial Statement Overview

Summary
ProQR demonstrates strong revenue growth, especially in the TTM period, but struggles with profitability. The balance sheet is stable with low leverage, yet negative return on equity and cash flow issues are concerning. The company needs to address profitability and cash flow to improve its financial health.
Income Statement
45
Neutral
ProQR shows a significant increase in revenue over the years, with a notable revenue growth from 2023 to TTM (Trailing-Twelve-Months). However, the company struggles with profitability, as evidenced by negative EBIT and net income margins. The gross profit margin remains positive, indicating efficient cost management at the production level, but high operating expenses lead to negative net margins.
Balance Sheet
50
Neutral
The balance sheet reflects a moderate financial position with a debt-to-equity ratio of 0.21 in TTM, indicating manageable leverage. The equity ratio is 52.0%, suggesting a healthy proportion of equity financing. However, the company has consistently reported negative net income, impacting return on equity, which remains negative.
Cash Flow
40
Negative
ProQR's cash flow statement shows challenges in generating positive free cash flow, with negative free cash flow growth in TTM. The operating cash flow to net income ratio is negative, indicating issues in converting earnings into cash. Despite this, the company has managed to maintain liquidity through financing activities.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue18.91M6.51M4.04M1.35M0.00
Gross Profit18.91M6.38M1.56M1.35M-2.19M
EBITDA-24.12M-24.10M-56.46M-54.95M-136.56M
Net Income-27.76M-28.12M-64.89M-61.68M-46.61M
Balance Sheet
Total Assets167.96M137.88M171.32M209.58M98.73M
Cash, Cash Equivalents and Short-Term Investments149.41M118.92M94.78M187.52M75.84M
Total Debt17.22M19.73M21.97M60.37M34.28M
Total Liabilities79.40M96.49M106.21M96.35M42.18M
Stockholders Equity88.56M41.39M65.50M113.83M57.09M
Cash Flow
Free Cash Flow-37.81M20.18M-69.22M-26.50M-47.98M
Operating Cash Flow-36.39M21.55M-68.51M-26.01M-47.06M
Investing Cash Flow-4.07M4.28M-702.00K-425.00K-924.00K
Financing Cash Flow70.28M-2.27M-30.89M136.83M14.50M

ProQR Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price2.10
Price Trends
50DMA
2.03
Positive
100DMA
1.76
Positive
200DMA
2.33
Negative
Market Momentum
MACD
0.04
Positive
RSI
45.67
Neutral
STOCH
9.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Neutral. The current price of 2.1 is below the 20-day moving average (MA) of 2.26, above the 50-day MA of 2.03, and below the 200-day MA of 2.33, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 45.67 is Neutral, neither overbought nor oversold. The STOCH value of 9.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRQR.

ProQR Risk Analysis

ProQR disclosed 79 risk factors in its most recent earnings report. ProQR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ProQR Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
$277.22M-91.44%-2.04%83.49%
55
Neutral
$125.34M-24.73%-1.02%-8.59%
54
Neutral
$138.40M87.50-24.22%-23.40%17.80%
52
Neutral
$291.41M-99.23%-40.10%-16.60%
51
Neutral
$7.35B0.50-65.61%2.47%15.28%1.44%
51
Neutral
$218.84M-52.64%82.38%3.63%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRQR
ProQR
2.08
0.18
9.47%
CGEN
Compugen
1.48
-0.16
-9.76%
TNXP
Tonix Pharma
39.01
-6.19
-13.69%
SLN
Silence Therapeutics
6.17
-11.01
-64.09%
SEER
Seer
2.13
0.36
20.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025